Sanofi wins US approval of new intradermal flu shot, with 90% smaller needle
This article was originally published in Scrip
Executive Summary
Sanofi Pasteur, the vaccines division of Sanofi, won US approval on 10 May for its intradermal microinjection influenza vaccine Fluzone Intradermal, which uses an ultra-fine needle that is 90% smaller than syringes used for intramuscular injection of standard flu shots.